Compounded
Semaglutide
Any prescribed dose up to 2.5 mg/week
Prescription & clinician review included
Shipping included
$948 due today
Compounded semaglutide runs $99 to $299 a month. Wegovy runs $650 to $1,599. The gap is real and so is the reason for it: compounded drugs are not FDA-approved, and since both shortages resolved the legal basis for making them narrowed sharply. This is what the difference actually is.
This is why we ask every provider we review to name the pharmacy that fills its prescriptions, and why we flag it as a negative when they will not. A named pharmacy can be looked up — you can check its state licensure, its 503A or 503B status, and whether it has an inspection or recall history. An unnamed one cannot be checked at all. Across the providers we have reviewed, refusal to name the pharmacy is the single most common transparency gap.
Be alert to providers still citing shortages as their rationale. In reviewing telehealth GLP-1 providers we have found sites in 2026 still explaining their compounded offerings by reference to "high demand and national shortages" — a regulatory situation that ended between eighteen months and two years ago. Rixa Health is one example we documented. A provider whose stated legal basis is out of date is telling you something about how closely it is tracking the rules it operates under.
The question to ask, in writing: "Now that the shortages have resolved, what is the individual clinical basis for compounding this medication for me?" A good provider will have an answer — a dose not commercially available, a documented excipient issue. A provider that responds with marketing language, or does not respond, has answered a different and more useful question.
A separate and more serious category: watch for providers advertising drugs that are not approved at all. Retatrutide is an Eli Lilly investigational triple agonist still in Phase 3 trials — Lilly stated on July 23, 2026 that it intends to file for approval in Q1 2027. It is not FDA-approved for any use and it is not on the FDA's 503A bulk drug substances list, which is the specific legal reason a compounding pharmacy cannot make it. We found it named on at least one telehealth provider's site with no investigational-status disclaimer. If you see retatrutide offered for sale, that is not an early-access opportunity.
You can check any company yourself in about two minutes. The FDA maintains a public, searchable warning letter database — search the company name. In a market where nearly every quality claim is self-reported by the seller, the warning letter database is one of the very few sources that is neither marketing nor a review site. We run this check on every provider we review, and we tell you what we find either way.
Notice what sits at the top of that table. The cheapest option on the entire list is an FDA-approved brand-name drug — if your insurance covers it. Many people shopping compounded GLP-1s have never checked their own plan's weight-loss medication coverage, or checked once during the shortage era and never again. That single phone call is the highest-value step in this whole process, and it is free.
Manufacturer direct-pay programmes have also narrowed the gap substantially. Zepbound through LillyDirect starts around $349/month cash-pay — well below the $650–$1,100 telehealth brand pricing and within reach of the upper end of compounded maintenance costs. If the price difference between compounded and brand-name is the only thing pushing you toward compounded, price the manufacturer's own direct channel before deciding.
Two things that should stop you regardless of price: a provider offering a drug that is not FDA-approved for any indication (retatrutide being the current example), and a provider who will not tell you which pharmacy is making your medication. Neither is a pricing question. Both are about whether anyone is accountable for what is in the vial.
This article is for informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare provider before making decisions about your health or medications. Individual experiences may vary.
Med Consumer Watch GLP-1 plans
Med Consumer Watch exists to help consumers make informed choices. Our brand brings that mission to GLP-1 care: clear plan prices, clinician review and support included, so you can compare your options and get started with confidence.
Medication, clinician review and shipping are included. See your total before you buy.
Your plan price stays the same across its included prescribed doses. Choose 1, 3, 6 or 12 months.
Ongoing doctor messaging, health coaching and patient community access are included with your plan.
Choose your medication and the plan length that works for you.
Compounded
Any prescribed dose up to 2.5 mg/week
Prescription & clinician review included
Shipping included
$948 due today
Compounded
Any prescribed dose up to 15 mg/week
Prescription & clinician review included
Shipping included
$1,548 due today
Treatment requires a prescription and clinician approval. If treatment is declined, your payment is refunded. Compounded medications are not FDA-approved.
Enter for a chance to use it toward eligible CoreAge Rx products and services.
The gift card may be applied toward eligible CoreAge Rx products and services. Prescription products additionally require completing the intake process and evaluation by a licensed healthcare provider, who alone decides eligibility and treatment. Winning does not guarantee that you will qualify for a GLP-1 medication or any other prescription treatment.